| Ytd | 22.76% | |
| 1y | 10.69% |
| Open | 9.37 | Prev Close | 9.42 | Low | 9.36 | High | 9.53 | Mkt Cap | 1.98B |
| Vol | 210.62K | Avg Vol | 4.99M | EPS | 1.30 | P/E | 7.25 | Forward P/E | 11.30 |
| Beta | 0.55 | Short Ratio | 8.38 | Inst. Own | 101.37% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-03 | 50-d Avg | 9.20 | 200-d Avg | 8.14 | 1yr Est | 21.90 |
BCRX News
RESEARCH TRIANGLE PARK, N.C., July 22, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasd
RESEARCH TRIANGLE PARK, N.C., July 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasd
The consensus price target hints at an 118% upside potential for BioCryst (BCRX). While empirical re
JP Morgan analyst Jessica Fye reinstates BioCryst Pharma (NASDAQ:BCRX) with a Neutral and announc
BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend
RBC Capital analyst Brian Abrahams maintains BioCryst Pharma (NASDAQ:BCRX) with a Outperform and
RESEARCH TRIANGLE PARK, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasd
HC Wainwright & Co. analyst Andrew S. Fein maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy
Wall Street analysts changed outlook on top names. Wedbush raised Replimune's price target, Cana
Cantor Fitzgerald analyst Steven Seedhouse maintains BioCryst Pharma (NASDAQ:BCRX) with a Overwei
BioCryst Pharmaceuticals said on Monday it would wind down its internal drug discovery programs and
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) ("BioCryst" or the "Company") today ann
—Advances strategic shift toward a disciplined research model prioritizing external innovation to ac
BioCryst Pharmaceuticals, Inc. is upgraded to Buy, reflecting strong execution in HAE and a compelli
— Growing body of ORLADEYO ® clinical data and real-world evidence demonstrates consistent reduction
RESEARCH TRIANGLE PARK, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasd
RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasda
RESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasda
BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Bank of America Global Healthcare Conference 2026
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) reported upbeat earnings for the first quarter on Wednesd
BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2026 Earnings Call Transcript
BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.03 per share versus the Zacks C
— Q1 2026 ORLADEYO ® net revenue of $148.3 million (+11% y-o-y; +21% y-o-y on comparable basis exclu
RESEARCH TRIANGLE PARK, N.C., May 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasda
— BioCryst grants Irish affiliate of Neopharmed Gentili exclusive license to commercialize navenibar
RESEARCH TRIANGLE PARK, N.C., April 28, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nas
PAVS stock rose 65.6% in pre-market trading after ending sales agreement with A.G.P/Alliance Global
Retail investors are preparing for another busy week of earnings season with more than 1,600 compani
On Thursday, 369 companies hit new 52-week lows.
On Tuesday, 647 companies set new 52-week lows.
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is likely to report earnings for its f
On Wednesday, 807 companies reached new 52-week lows.
On Friday, 1043 companies hit new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
Before 10 a.m. ET Monday, 296 stocks made new 52-week highs.